US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out the viral code from human cells and tissues.

Globally, people get animal protein mostly from chickens, with pigs and cattle in second and third place. A 2023 report ...

Mice with active infections had EcoHIV, the mouse equivalent of human HIV-1. Using CRISPR/Cas9, researchers were able to block replication of the virus and show they could potentially prevent ...

Although antiretroviral therapies can contain HIV in the long term by preventing ... regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9).

Penn has undergone numerous advancements, including the creation of new undergraduate majors, campus development projects, ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. CRISPR Therapeutics (NasdaqGM:CRSP) recently announced its Q1 2025 earnings, reporting a 71% ...